JP2017525668A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525668A5
JP2017525668A5 JP2016575768A JP2016575768A JP2017525668A5 JP 2017525668 A5 JP2017525668 A5 JP 2017525668A5 JP 2016575768 A JP2016575768 A JP 2016575768A JP 2016575768 A JP2016575768 A JP 2016575768A JP 2017525668 A5 JP2017525668 A5 JP 2017525668A5
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
compound
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016575768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525668A (ja
JP6663866B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/038345 external-priority patent/WO2016003917A1/en
Publication of JP2017525668A publication Critical patent/JP2017525668A/ja
Publication of JP2017525668A5 publication Critical patent/JP2017525668A5/ja
Application granted granted Critical
Publication of JP6663866B2 publication Critical patent/JP6663866B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016575768A 2014-07-03 2015-06-29 リジン特異的なデメチラーゼ−１の阻害剤 Expired - Fee Related JP6663866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03
US62/020,886 2014-07-03
PCT/US2015/038345 WO2016003917A1 (en) 2014-07-03 2015-06-29 Inhibitors of lysine specific demethylase-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019029856A Division JP6768857B2 (ja) 2014-07-03 2019-02-21 リジン特異的なデメチラーゼ−１の阻害剤

Publications (3)

Publication Number Publication Date
JP2017525668A JP2017525668A (ja) 2017-09-07
JP2017525668A5 true JP2017525668A5 (enExample) 2018-05-31
JP6663866B2 JP6663866B2 (ja) 2020-03-13

Family

ID=55019883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575768A Expired - Fee Related JP6663866B2 (ja) 2014-07-03 2015-06-29 リジン特異的なデメチラーゼ−１の阻害剤
JP2019029856A Expired - Fee Related JP6768857B2 (ja) 2014-07-03 2019-02-21 リジン特異的なデメチラーゼ−１の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019029856A Expired - Fee Related JP6768857B2 (ja) 2014-07-03 2019-02-21 リジン特異的なデメチラーゼ−１の阻害剤

Country Status (29)

Country Link
US (3) US9902719B2 (enExample)
EP (2) EP3164380B1 (enExample)
JP (2) JP6663866B2 (enExample)
KR (1) KR102475498B1 (enExample)
CN (2) CN108530424B (enExample)
AU (1) AU2015284383B2 (enExample)
BR (1) BR112017000043A2 (enExample)
CA (1) CA2954049A1 (enExample)
CL (1) CL2016003422A1 (enExample)
CO (1) CO2017000549A2 (enExample)
CY (1) CY1125127T1 (enExample)
DK (2) DK3511319T3 (enExample)
EA (2) EA033698B1 (enExample)
EC (1) ECSP17006821A (enExample)
ES (2) ES2907676T3 (enExample)
FI (1) FI3511319T3 (enExample)
HR (2) HRP20220414T1 (enExample)
HU (2) HUE058852T2 (enExample)
IL (2) IL249881B (enExample)
LT (2) LT3511319T (enExample)
MX (2) MX395534B (enExample)
PL (2) PL3511319T3 (enExample)
PT (2) PT3164380T (enExample)
RS (2) RS63074B1 (enExample)
SA (1) SA517380651B1 (enExample)
SG (2) SG11201610975RA (enExample)
SI (2) SI3511319T1 (enExample)
SM (2) SMT202200136T1 (enExample)
WO (1) WO2016003917A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016275702A1 (en) 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
FI3661510T3 (fi) 2017-08-03 2024-12-18 Oryzon Genomics Sa Menetelmiä käyttäytymismuutosten hoitamiseksi
CN112601750B (zh) * 2018-08-10 2023-10-31 纳维尔制药有限公司 Ptpn11（shp2）抑制剂
US12479845B2 (en) 2019-02-01 2025-11-25 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same
CN113365996B (zh) * 2019-02-01 2024-09-03 韩美药品株式会社 咪唑吡啶衍生化合物以及药物组成物
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
LT3941466T (lt) 2019-03-20 2026-02-25 Oryzon Genomics, S.A. Vafidemstatas ribinio asmenybės sutrikimo simptomų, nesusijusių su agresija, gydymui
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
WO2022188709A1 (zh) * 2021-03-11 2022-09-15 南京明德新药研发有限公司 噻吩类化合物及其应用
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
US20250073232A1 (en) 2021-04-08 2025-03-06 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
AU2002214546A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp Ｌ−プロリン誘導体およびその医薬としての用途。
KR101146849B1 (ko) * 2003-12-11 2012-05-16 미쓰비시 타나베 파마 코퍼레이션 α-아미노산 유도체 및 그 의약 용도
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
AU2006287202B2 (en) * 2005-09-01 2013-01-24 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
JP2007197324A (ja) 2006-01-23 2007-08-09 Toray Ind Inc ２，４，５−置換−１，３−アゾール誘導体
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
US20130096160A1 (en) 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
EP2822946A1 (en) * 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
CA3161836A1 (en) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
BR112016018691A2 (pt) * 2014-02-14 2017-08-08 Univ British Columbia Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso
KR102400920B1 (ko) * 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
DK3160956T3 (da) * 2014-06-27 2020-08-31 Celgene Quanticel Res Inc Inhibitorer af lysin-specifik demethylase-1
JP6525422B2 (ja) * 2014-07-03 2019-06-05 セルジーン クオンティセル リサーチ，インク． リジン特異的なデメチラーゼ−１の阻害剤

Similar Documents

Publication Publication Date Title
JP2017525668A5 (enExample)
JP2017514830A5 (enExample)
JP2017521407A5 (enExample)
JP2017519781A5 (enExample)
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
JP2010526129A5 (enExample)
JP2017502940A5 (enExample)
HRP20220414T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2012501312A5 (enExample)
JP2016540742A5 (enExample)
CA2687625C (en) 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
JP2020502092A5 (enExample)
AU2013355054B2 (en) Diazole lactams
JP2018527295A5 (enExample)
JP2017533968A5 (enExample)
JP2011510929A5 (enExample)
JP2013509392A5 (enExample)
DK2935227T3 (en) DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
JP2011505347A5 (enExample)
JP2006501201A5 (enExample)
FI3546462T3 (fi) Uusi oksoisokinoliinijohdannainen
RU2009139915A (ru) Производные имидазолидинона
RU2015101102A (ru) Гетероароматическое метильное производное циклического амина
JP2011513475A5 (enExample)
JP2017510595A5 (enExample)